AI Verdict
INVA has stronger fundamentals based on our AI analysis.
IOBT vs INVA Fundamental Comparison
| Metric | IOBT | INVA |
|---|---|---|
| Revenue | N/A | $411.3M |
| Net Income | $-57.0M | $271.2M |
| Net Margin | N/A | 65.9% |
| ROE | -6,258.6% | 23.1% |
| ROA | -142.7% | 16.6% |
| Current Ratio | 2.01x | 14.64x |
| Debt/Equity | 18.29x | 0.22x |
| EPS | $-0.86 | $3.30 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
IOBT vs INVA: Frequently Asked Questions
Is IOBT or INVA a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), INVA has stronger fundamentals. IOBT is rated STRONG SELL (95% confidence) while INVA is rated STRONG BUY (92% confidence). This is not investment advice.
How does IOBT compare to INVA fundamentally?
IO Biotech, Inc. has ROE of -6,258.6% vs Innoviva, Inc.'s 23.1%. Net margins are N/A vs 65.9% respectively.
Which stock pays higher dividends, IOBT or INVA?
IOBT has a dividend yield of N/A or no dividend while INVA has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in IOBT or INVA for long term?
For long-term investing, consider that IOBT has STRONG SELL rating with 95% confidence, while INVA has STRONG BUY rating with 92% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about IOBT vs INVA?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For IOBT vs INVA, the AI consensus favors INVA based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.